Humana focuses on Hepatitis C medications Sovaldi and Harvoni

25 июля 2015, 07:58

Pharmaceutical company Humana has initiated a deal with Gilead Sciences to exceptionally introduce the company's two effective Hepatitis C virus -HCV drugs, Sovaldi (Sofosbuvir) and Harvoni (Ledipasvir/Sofosbuvir) for patients searching for much-promising treatment, Modern Healthcare informs. This company's declaration is the latest in a row of news concerning pricing wars between health insurers, managers specialized in pharmaceutical benefits and medications producers nationwide.

There took place two medical innovations in Hepatitis C treatment within two years:

1. In December 2013, the FDA authorized Gilead's Sovaldi for usage in combination with other antiviral drugs for the treatment of chronic Hepatitis C (genotypes 1, 2, 3 and 4). The Sovaldi course offers a predicted cure within a short course of treatment.

2. In October 2014, the FDA authorized Gilead's Harvoni, the first and only Hepatitis C treatment contained in a single tablet, received orally once daily lasting eight, 12 or 24 weeks. Harvoni combines Sovaldi with Gilead's Ledipasvir, an NS5A inhibitor.

Since the detection of the virus in 1989, treating Hepatitis C has symbolized a challenge for both a doctor and patient. There was needed an effective and quick remedy. During many years, the only known treatment options were not effective for many patients and often difficult to endure.

First treatment courses consisted of year of weekly Interferon injections and Ribavirin tablets lasting a year, which lead to serious side effects such as depression, nausea, severe reductions in certain blood cells and flu-like symptoms.

These often not tolerable treatment courses, mixed with low cure rates, made many patients to cease treatment before it actually had to be over.

The situation is different today. In comparison to other serious chronic diseases, Hepatitis C turns out to have the potential to be cured.

The introduction of Gilead's Hepatitis C treatments represents the dramatical clinical, economic and public health significance that Sovaldi and Harvoni open to patients, their families and healthcare system. This is an alternative to less effective regimens.

By rapidly curing the most part of patients, Gilead's Hepatitis C treatments may reduce the frequency of healthcare visits and admission to hospital, and decrease the need for medications to cope with adverse reactions and complications.

При поддержке: digital агентство Webmart Group

Рейтинг Яндекс.Метрика

с (c) Все права защищены